INTRODUCTION AND OBJECTIVES: Holmium laser enucleation of the prostate (HoLEP) in BPH is widely used and the effects are known to be equivalent or better than traditional TUR-P with low incidence of complications. However, some patients who underwent HoLEP still have the lower urinary tract symptoms(LUTS) after surgery. We evaluated the characteristics of patients who visited our clinics due to persistent LUTS and required additional medications after HoLEP in BPH patients.
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METHODS: The medical records of the patients who underwent HoLEP from March of 2011 to June of 2015 were reviewed retrospectively. The analysis was performed in patients who have been followed for more than 6 months after surgery. The patients were divided into 2 groups. Group A is the patients with persistent obstructive symptoms and group B is with irritation symptoms. Age, prostate specific antigen, International prostate symptom score (IPSS), prostate volume, transition zone volume of prostate, peak flow rate, maximum cystometric capacity, post voided residual volume, resected weights, operation time were analyzed. RESULTS: Among the 482 patients who underwent the HoLEP, the numbers of patients who required the medicine for lower urinary tract symptoms were 138 (28.6%). Among the patients, 53 patients (40.2%) were enrolled in Group A and 85 patients (59.8%) were enrolled in Group B. The mean age, total IPSS, PSA, total prostate volume, peak flow rate, maximum cystometric capacity, post voided residual volume, and operation time between two groups were statistically insignificant. However, transition zone volume and resected weights were significantly different between group A and B. (p¼0.017, p¼0.010 respectively) CONCLUSIONS: More than 25% of the patients were still taking the medicines for lower urinary tract symptoms after HoLEP. Among the patients who required the medicine, 60% of patients have complained of irritation symptoms. Bigger transition zone with resection weights were correlated with remaining of postoperative irritation symptoms. (ICS, 2002) suggested the qualification of urodynamic DO as according to their pattern (phasic or terminal) or causes (neurogenic or idiopathic). However, quantification of DO has not been suggested. It is well known that there are some discordances between urodynamic DO and actual storage symptoms such e328 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 
